Clearmind Medicine plans 1-for-8 reverse split

The split also leaves authorized share capital unchanged and proportionately adjusts outstanding option and warrant terms.

Rhea-AI Filing Summary

Clearmind Medicine Inc. (CMND) will effect a 1-for-8 reverse split of its common shares, with split-adjusted trading on the Nasdaq Capital Market beginning October 5, 2026. Issued and outstanding common shares will adjust from 4,059,227 to 507,404, subject to further adjustments based on the treatment of fractional shares. No fractional shares will be issued; fractions will be rounded up to the nearest whole common share. The split will proportionately adjust the per-share exercise price and number of shares issuable under outstanding options and warrants. Authorized share capital will remain unchanged.

Key Figures

Reverse split ratio: 1-for-8 Issued and outstanding common shares before split: 4,059,227 shares Issued and outstanding common shares after split: 507,404 shares +1 more

4 metrics

Reverse split ratio 1-for-8 Clearmind Medicine Inc. common shares

Issued and outstanding common shares before split 4,059,227 shares Before the reverse split

Issued and outstanding common shares after split 507,404 shares Subject to further adjustments based on the treatment of fractional shares

Split-adjusted trading date October 5, 2026 Nasdaq Capital Market

Key Terms

reverse share split, authorized share capital, fractional shares, per share exercise price

4 terms

reverse share split technical

"will effect a reverse share split"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

authorized share capital financial

"authorized share capital will remain unchanged"

The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.

fractional shares technical

"No fractional Common Shares will be issued"

Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.

per share exercise price financial

"adjustment will be made to the per share exercise price"

Stock Split

1-for-8 reverse split · Effective October 5, 2026

Split Ratio 1-for-8 reverse split

Effective Date October 5, 2026

Shares Before Split 4,059,227

Shares After Split 507,404

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is CMND's reverse split ratio and when will split-adjusted trading begin?

Clearmind Medicine Inc. will effect a 1-for-8 reverse split, and its ordinary shares will begin trading on the Nasdaq Capital Market after implementation on October 5, 2026.

How many CMND common shares will be issued and outstanding after the reverse split?

The number of issued and outstanding common shares will adjust from 4,059,227 to 507,404, subject to further adjustments based on the treatment of fractional shares.

How will CMND handle fractional shares in the reverse split?

No fractional common shares will be issued. Fractional shares will be rounded up to the nearest whole common share.

How will the CMND reverse split affect outstanding options and warrants?

The per-share exercise price and the number of common shares issuable upon exercise of all outstanding options or warrants will be adjusted proportionately.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 04:30 PM Accepted by SEC EDGAR 09/30/2026 - 04:30 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

CONTENTS

Clearmind Medicine Inc. (the “Company”) is announcing that it will effect a reverse share split of the Company’s common shares at the ratio of 1-for-8, such that each eight (8) common shares, no par value, shall be consolidated into one (1) common share, no par value. The first date when the Company’s ordinary shares will begin trading on the Nasdaq Capital Market after implementation of the reverse split will be Monday, October 5, 2026.

Following the implementation of the reverse split, the Company’s authorized share capital will remain unchanged. The reverse split will adjust the number of issued and outstanding common shares of the Company from 4,059,227 ordinary shares to 507,404 ordinary shares (subject to any further adjustments based on the treatment of fractional shares).

‍No fractional Common Shares will be issued as a result of the reverse split. All fractional shares shall be rounded up to the nearest whole common share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of common shares issuable upon the exercise of all outstanding options or warrants entitling the holders thereof to purchase common shares. The new CUSIP number for the ordinary shares will be 185053709.

This Report on Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: September 30, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

2